الصفحة الرئيسية>>Signaling Pathways>> Endocrinology and Hormones>> Androgen Receptor>>Proxalutamide (GT0918)

Proxalutamide (GT0918) (Synonyms: GT0918; Pruxelutamide)

رقم الكتالوجGC33224

يعتبر Proxalutamide (GT0918) (GT0918) أحد مضادات مستقبلات الأندروجين الفعالة عن طريق الفم. يمكن استخدام Proxalutamide (GT0918) (GT0918) في دراسة سرطان البروستاتا و COVID-19.

Products are for research use only. Not for human use. We do not sell to patients.

Proxalutamide (GT0918) التركيب الكيميائي

Cas No.: 1398046-21-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
434٫00
متوفر
5mg
381٫00
متوفر
10mg
648٫00
متوفر
25mg
1350٫00
متوفر
50mg
2287٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of Proxalutamide (GT0918)

Proxalutamide (GT0918) is a potent androgen receptor (AR) antagonist.

In biochemical assay, Proxalutamide (GT0918) more potently inhibits androgen binding with AR's ligand binding domain than Bicalutamide (11.4x) and MDV3100 (3.5x). In both hormone-sensitive (LNCaP) and CRPC (C4-2) cancer cells, Proxalutamide demonstrates stronger potency to block AR function of gene transcription than Bicalutamide (~5-10) and MDV3100 (2-5x) while maintaining full antagonism in CRPC cells. Proxalutamide impairs androgen stimulates AR translocation to cell nuclei hence blocks its binding DNA and shuts down the downstream oncogenic signaling. Moreover, Proxalutamide induces AR down regulation in prostate cancer cells. Proxalutamide not only inhibits proliferation of hormone-sensitive CaP cells, but also more potently inhibits proliferation of CRPC cells. In addition, Proxalutamide inhibits the growth of AR positive breast cancer cells. In contrast, Proxalutamide has minimum effects on the growth of AR-negative CaP cells (PC-3 and DU145), indicating it is a selective AR pathway inhibitor[1].

The major pharmacokinetic parameters and statistical moment parameters are summarized. The tmax for the pHM-SD and conventional tablets are 0.9±0.4 h and 2.5±1.1 h, respectively, meaning that the pHM-SD tablets dissolve more quickly than the conventional tablets. Moreover, the difference between the tmax of the two treatments is statistically significant (p<0.05). The mean Cmaxand the AUC0-36 are 5.1±2.4 μg/mL and 38.3±8.2 μgh/mL for the pHM-SD tablets versus 3.1±1.5 μg/mL and 42.1±22.3 μgh/mL for conventional tablets, respectively. The relative bioavailability (frel) of the pHM-SD tablets is 125.6% of that for the conventional tablets on average, revealing that the bioavailability of the former is higher. The mean Proxalutamide (GT0918) half-life estimate from the pHM-SD tablets (7.9±2.2 h) was similar to that of the conventional tablets (8.4±0.5 h), remaining consistent with the following pharmacoki-netic theory: the extent and rate of absorption should not affect elimination[2].

[1]. Youzhi Tong, et al. Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor. Cancer Research. AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. [2]. Yang M, et al. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo. Int J Pharm. 2014 Nov 20;475(1-2):97-109.

Protocol of Proxalutamide (GT0918)

Animal experiment:

Beagle Dogs[2]A single dose (25 mg Proxalutamide), randomized study with a two period crossover design is carried out to assess the pharmacoki-netics. Six healthy beagle dogs (9.3±0.7 kg) are randomly divided into two groups and fasted with free access to water overnight. Each group is orally administered with pHM-SDs tablet (Test) or a conventional tablet followed by 50 mL of water, respectively. The dogs obtain free access to water and food 6 h after drug administration. After a 1-week washout period, the groups are inverted and the administrations are repeated. A series of blood samples (1 mL) is collected in heparinized tubes using an indwelling cannula at pre-dose (-0.5 h) and post-dose (0.5, 1, 1.5, 2, 2.5 4, 6, 12, 24, 30, 36 and 48 h); these samples are gently mixed and centrifuged at 4000 rpm for 10 min within 1 h of collection[2].

References:

[1]. Youzhi Tong, et al. Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor. Cancer Research. AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA.
[2]. Yang M, et al. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo. Int J Pharm. 2014 Nov 20;475(1-2):97-109.

Chemical Properties of Proxalutamide (GT0918)

Cas No. 1398046-21-3 SDF
المرادفات GT0918; Pruxelutamide
Canonical SMILES N#CC1=CC=C(N(C(N(C2=CC=C(CCCC3=NC=CO3)N=C2)C4(C)C)=S)C4=O)C(F)=C1C(F)(F)F
Formula C24H19F4N5O2S M.Wt 517.5
الذوبان Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Proxalutamide (GT0918)

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 1.9324 mL 9.6618 mL 19.3237 mL
5 mM 0.3865 mL 1.9324 mL 3.8647 mL
10 mM 0.1932 mL 0.9662 mL 1.9324 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of Proxalutamide (GT0918)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for Proxalutamide (GT0918)

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Proxalutamide (GT0918)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.